ArticleBMC genomics2016
Estimating survival time of patients with glioblastoma multiforme and characterization of the identified microRNA signatures.
Article in BMC genomics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Prognostic Role of MicroRNA 222 in Patients with Glioma: A Meta-analysis.BioMed research international · 2020Pooled it
- An evolutionary learning-based method for identifying a circulating miRNA signature for breast cancer diagnosis prediction.NAR genomics and bioinformatics · 2024Article
- Glutathione PeroxidaseGenes · 2023Article
- Artificial intelligence-driven pan-cancer analysis reveals miRNA signatures for cancer stage prediction.HGG advances · 2023Article
- Article
- The intra-tumoral heterogeneity in glioblastoma - a limitation for prognostic value of epigenetic markers?Acta neurochirurgica · 2023Article
- Molecular and Circulating Biomarkers in Patients with Glioblastoma.International journal of molecular sciences · 2022Review
- MicroRNA signature for estimating the survival time in patients with bladder urothelial carcinoma.Scientific reports · 2022Article
- Versatile role of miR-24/24-1*/24-2* expression in cancer and other human diseases.American journal of translational research · 2022Review
- A Novel Prediction Model for Brain Glioma Image Segmentation Based on the Theory of Bose-Einstein Condensate.Frontiers in medicine · 2022Article
- Article
- Identification of the miRNA signature associated with survival in patients with ovarian cancer.Aging · 2021Article
- Prognostic Value of microRNA-221/2 and 17-92 Families in Primary Glioblastoma Patients Treated with Postoperative Radiotherapy.International journal of molecular sciences · 2021Article
- The clinical significance of glutathione peroxidase 2 in glioblastoma multiforme.Translational neuroscience · 2021Article
- Predicting the Risk Genes of Autism Spectrum Disorders.Frontiers in genetics · 2021Article
- lncRNA PANTR1 Upregulates BCL2A1 Expression to Promote Tumorigenesis and Warburg Effect of Hepatocellular Carcinoma through Restraining miR-587.Journal of immunology research · 2021Article
- Article
- MicroRNA-24 in Cancer: A Double Side Medal With Opposite Properties.Frontiers in oncology · 2020Review
- Identification and characterization of the lncRNA signature associated with overall survival in patients with neuroblastoma.Scientific reports · 2019Article
- Downregulated Expression of hsa_circ_0005556 in Gastric Cancer and Its Clinical Significance.Disease markers · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThough glioblastoma multiforme (GBM) is the most frequently occurring brain malignancy in adults, clinical treatment still faces challenges due to poor prognoses and tumor relapses. Recently, microRNAs (miRNAs) have been extensively used with the aim of developing accurate molecular therapies, because of their emerging role in the regulation of cancer-related genes. This work aims to identify the miRNA signatures related to survival of GBM patients for developing molecular therapies.
resultsThis work proposes a support vector regression (SVR)-based estimator, called SVR-GBM, to estimate the survival time in patients with GBM using their miRNA expression profiles. SVR-GBM identified 24 out of 470 miRNAs that were significantly associated with survival of GBM patients. SVR-GBM had a mean absolute error of 0.63 years and a correlation coefficient of 0.76 between the real and predicted survival time. The 10 top-ranked miRNAs according to prediction contribution are as follows: hsa-miR-222, hsa-miR-345, hsa-miR-587, hsa-miR-526a, hsa-miR-335, hsa-miR-122, hsa-miR-24, hsa-miR-433, hsa-miR-574 and hsa-miR-320. Biological analysis using the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway on the identified miRNAs revealed their influence in GBM cancer.
conclusionThe proposed SVR-GBM using an optimal feature selection algorithm and an optimized SVR to identify the 24 miRNA signatures associated with survival of GBM patients. These miRNA signatures are helpful to uncover the individual role of miRNAs in GBM prognosis and develop miRNA-based therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.